Shares of Gilead Sciences (NASDAQ:GILD) rose by just over 2% Friday after the company publicized a report that used a controversial method of analysis to suggest that its experimental antiviral drug, remdesivir, greatly improves patients' chances of surviving a case of COVID-19.The FDA hasn't levied any specific threats, but that EUA will be skating on thin ice as soon as some other experimental treatment in development produces more convincing efficacy results.